A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervixReport as inadecuate




A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix - Download this document for free, or read online. Document in PDF available to download.

Radiation Oncology

, 9:55

Clinical Radiation Oncology

Abstract

BackgroundTo evaluate the efficacy and safety of concurrent chemo-radiotherapy with weekly nedaplatin for the treatment of advanced squamous cell carcinoma of the uterine cervix.

MethodsPatients with stage Ib2 to IIIb squamous cell carcinoma of the uterine cervix were treated with concurrent radiotherapy and chemotherapy. The radiotherapy regimen included external beam radiation therapy 45–50.4Gy-25-28 fractions with central shielding after 30.6Gy and high-dose-rate brachytherapy irradiation 35-49Gy-5-7 fractions to point A. The chemotherapy regimen was weekly intravenous infusion of nedaplatin 30 mg-m, once weekly, 180 mg-m for 6 weeks.

ResultsThirty patients were enrolled in this study from April 2010 to October 2010. The median age was 50.5 years 34–62. Three patients were at the clinical stage IIa2, twenty at stage IIb and seven at stage IIIb. Acute hematological toxicities included grade 3 leukopenia 8, neutropenia 5, anemia 2, grade 4 anemia 1, and grade 2 thrombocytopenia 6. Acute non-hematological toxicities included grade 2 liver disorders 1, diarrhea 2, nausea 2, and renal toxicity 1. There were not grade 3 or worse toxicities. 24 patients completed the treatment regimen and were evaluated for efficacy. 23 patients 95.8% had CR complete response and 1 4.2% had PR partial response 100% response rate. The median follow-up duration was 36 months 23–39, during which three patients relapsed after the treatment. The 3-year PFS and OS rates were 87.5% and 91.7%, respectively.

ConclusionsThis phase II study suggested that concurrent chemo-radiotherapy with weekly nedaplatin was effective and safe for the treatment of advanced squamous cell carcinoma of the uterine cervix.

KeywordsNedaplatin Concurrent chemo-radiotherapy Advanced cervical carcinoma AbbreviationsCCRTThe concurrent chemo-radiotherapy

CRComplete response

NCINational Cancer Institute

OSThe overall survival

PDProgressive disease

PFSThe progression free survival

PRPartial response

SDStable disease.

Electronic supplementary materialThe online version of this article doi:10.1186-1748-717X-9-55 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Guangwen Yuan - Lingying Wu - Manni Huang - Nan Li - Jusheng An

Source: https://link.springer.com/







Related documents